| Outcome Measures: |
Primary: Pharmacokinetics-Cmax, Maximum observed concentration of HRS-1780, Start of Treatment to end of study (approximately 1 week)|Pharmacokinetics-AUC0-last, Area under the concentration-time curve from time 0 to last time point after HRS-1780 administration, Start of Treatment to end of study (approximately 1 week)|Pharmacokinetics-AUC0-inf, Area under the concentration-time curve from time 0 to infinity after HRS-1780 administration, Start of Treatment to end of study (approximately 1 week) | Secondary: Pharmacokinetics-Tmax, Time to Cmax of HRS-1780, Start of Treatment to end of study (approximately 1 week)|Pharmacokinetics-t1/2, Terminal elimination half-life of HRS-1780, Start of Treatment to end of study (approximately 1 week）|Pharmacokinetics-CL/F, Apparent clearance of HRS-1780, Start of Treatment to end of study (approximately 1 week)|Pharmacokinetics-Vz/F, Apparent volume of distribution during terminal phase of HRS-1780, Start of Treatment to end of study (approximately 1 week)|Pharmacokinetics-Cumulative excretion (Ae), Cumulative amount of HRS-1780 excreted in urine, Start of Treatment to end of study (approximately 1 week)|Pharmacokinetics-Cumulative excretion rate (Ae%), Cumulative percentage of HRS-1780 recovered in urine, Start of Treatment to end of study (approximately 1 week)|Pharmacokinetics-Renal clearance (CLr), Clearance of HRS-1780 by kidney, Start of Treatment to end of study (approximately 1 week)|Binding rates of plasma protein (BRPP) of HRS-1780, Binding rates of plasma protein, Start of Treatment to end of study (approximately 1 week)|Adverse events, Incidence and severity of adverse events, Start of Treatment to end of study (approximately 1 week)
|
